Dihydrooxadiazinones
The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R 1 , R 2 , R 3 , and R 4 , are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
1. A compound having the structure
(6S)-5-[4′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.
2. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipients.
3. A pharmaceutical combination comprising:
the compound of claim 1 , and
one or more further anti-cancer agents.
4. A method for the treatment of a disease sensitive to phosphodiesterase 3A (PDE3A) or phosphodiesterase 3B (PDE3B) modulation in a subject, comprising administering to the subject the compound of claim 1 .
5. The method according to claim 4 , wherein the disease is a hyperproliferative disease.
6. The method according to claim 5 , wherein the hyperproliferative disease is a cancer disease.
7. The method according to claim 6 , wherein the cancer disease is selected from brain cancer, breast cancer, cervical cancer, AML, lung cancer, skin cancer, esophageal carcinoma, ovarian cancer, pancreas cancer and prostate cancer.
8. The method according to claim 6 , wherein the cancer disease is selected from glioma, glioblastoma, and ovarian cancer.
9. The method according to claim 6 , wherein the cancer disease is melanoma.